

DIVI'S LABORATORIES LIMITED
1-72/23(P)/DIVIS/303. Divi Towers
Cyber Hills, Gachibowli, Hyderabad 500 032
Phone: 91-40-23786300 email: kishore@divislabs.com

PRESS RELEASE dated 26th May, 2017

Divi's Labs earns a Revenue of Rs. 4181 crores for FY17 on consolidated basis.

Consolidated for the year

For the year, Divi's Laboratories has earned a consolidated total revenue of Rs. 4181 crores for the financial year 2016-17 as against a total revenue of Rs. 3902 crores during the previous year.

PBT for the current year came to Rs. 1395 crores as against a PBT of Rs. 1393 crores for the previous year. PAT for the year is Rs. 1060 crores as against a PAT of Rs. 1126 crores for the last year.

This year, the company had a forex loss of Rs. 40 crores as against a forex gain of Rs. 37 crore during the last year. Staff cost for the year includes the one-time ex-gratia of Rs.79 crores paid to employees and whole-time directors of the company on the occasion of completion of 25 years' formation of the company.

Financial results have been prepared in accordance with the Indian Accounting Standards (Ind-AS) effective from this financial year. Revenue and Other Expenses include excise duty. Previous year's figures have also been recast to comply with Ind-AS and revised SEBI regulations.

Standalone Results

On a standalone basis, the company's earnings are as given below:

Rs. in crores

Particulars	For the Quarter		For the year	
	31-03-17	31-03-16	31-03-17	31-03-16
Total Revenue	1088	1121	4142	3846
PBT	350	385	1388	1375
PAT	259	322	1053	1111




Forex Gain/(loss)

Particulars of forex gain/(loss) for the period are given below:

Rs. in crores

	For the Quarter ended		For the year ended	
	31-03-17	31-03-16	31-03-17	31-03-16
Forex gain/(loss)	(29)	(2)	(39)	34

Dividend

The Board has recommended a dividend of Rs.10 per share i.e., 500% for the year subject to approval of members.

Exports constituted 88% of sales and about 73% to advanced markets in North America and Europe.

Capex:

During the year, the company has capitalized Fixed Assets amounted to Rs.242 crores. An amount of Rs.444 crores is carried forward as Capital WIP at the end of the year for the Capital Works under execution.

Update on US-FDA inspection

The Company has received a warning letter from US-FDA for its Unit-II at Visakhapatnam subsequent to issue of an Import Alert and its inspection of the facility during Nov-Dec, 2016. The US-FDA has also exempted several products from the Import Alert. The warning letter summarized the deviations from current Good Manufacturing Practices (CGMP) for active pharmaceutical ingredients (APIs) and also that its Investigators documented that the company limited and/or refused an FDA inspection.

The company has responded to the observations in Form-483 issued by the US-FDA and also to the warning letter within the stipulated time. The company engaged reputed consultants and subject matter experts for advising on the deviations observed and the remediation measures and to fully comply with the cGMP requirements.

